Stellar Biotechnologies Announces Exercise of Warrants Resulting in Cash Proceeds of $3 Million

LOS ANGELES, May 24, 2018 /PRNewswire/ — Stellar Biotechnologies, Inc. (Nasdaq: SBOT, “Stellar” or the “Company”), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting Alzheimer’s, lupus and cancers, among other diseases, today…